972 related articles for article (PubMed ID: 11334421)
1. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
2. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Muurling M; Mensink RP; Pijl H; Romijn JA; Havekes LM; Voshol PJ
Metabolism; 2003 Aug; 52(8):1078-83. PubMed ID: 12898477
[TBL] [Abstract][Full Text] [Related]
4. TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone.
Miles PD; Romeo OM; Higo K; Cohen A; Rafaat K; Olefsky JM
Diabetes; 1997 Nov; 46(11):1678-83. PubMed ID: 9356012
[TBL] [Abstract][Full Text] [Related]
5. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
6. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.
Ye JM; Frangioudakis G; Iglesias MA; Furler SM; Ellis B; Dzamko N; Cooney GJ; Kraegen EW
Endocrinology; 2002 Dec; 143(12):4527-35. PubMed ID: 12446579
[TBL] [Abstract][Full Text] [Related]
7. Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats.
Koopmans SJ; Kushwaha RS; DeFronzo RA
Metabolism; 1999 Mar; 48(3):330-7. PubMed ID: 10094109
[TBL] [Abstract][Full Text] [Related]
8. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.
Oakes ND; Camilleri S; Furler SM; Chisholm DJ; Kraegen EW
Metabolism; 1997 Aug; 46(8):935-42. PubMed ID: 9258278
[TBL] [Abstract][Full Text] [Related]
9. Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo.
Kalderon B; Mayorek N; Ben-Yaacov L; Bar-Tana J
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E795-803. PubMed ID: 12488241
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
11. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
[TBL] [Abstract][Full Text] [Related]
12. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Murakami K; Tobe K; Ide T; Mochizuki T; Ohashi M; Akanuma Y; Yazaki Y; Kadowaki T
Diabetes; 1998 Dec; 47(12):1841-7. PubMed ID: 9836514
[TBL] [Abstract][Full Text] [Related]
13. Plasma free fatty acids decrease insulin-stimulated skeletal muscle glucose uptake by suppressing glycolysis in conscious rats.
Kim JK; Wi JK; Youn JH
Diabetes; 1996 Apr; 45(4):446-53. PubMed ID: 8603766
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between adipose phosphoenolpyruvate carboxykinase and occurrence and reversion of insulin resistance].
Zhao WH; Xiao JZ; Yang WY; Wang N; Wang X; Chen XP; Bu S
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3074-8. PubMed ID: 16324411
[TBL] [Abstract][Full Text] [Related]
15. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Mayerson AB; Hundal RS; Dufour S; Lebon V; Befroy D; Cline GW; Enocksson S; Inzucchi SE; Shulman GI; Petersen KF
Diabetes; 2002 Mar; 51(3):797-802. PubMed ID: 11872682
[TBL] [Abstract][Full Text] [Related]
16. CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats.
de Souza CJ; Hirshman MF; Horton ES
Diabetes; 1997 Aug; 46(8):1257-63. PubMed ID: 9231648
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Kim JK; Fillmore JJ; Gavrilova O; Chao L; Higashimori T; Choi H; Kim HJ; Yu C; Chen Y; Qu X; Haluzik M; Reitman ML; Shulman GI
Diabetes; 2003 Jun; 52(6):1311-8. PubMed ID: 12765938
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.
Laplante M; Festuccia WT; Soucy G; Blanchard PG; Renaud A; Berger JP; Olivecrona G; Deshaies Y
Am J Physiol Regul Integr Comp Physiol; 2009 Jan; 296(1):R57-66. PubMed ID: 18971352
[TBL] [Abstract][Full Text] [Related]
19. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.
Halberstam M; Cohen N; Shlimovich P; Rossetti L; Shamoon H
Diabetes; 1996 May; 45(5):659-66. PubMed ID: 8621019
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
